Dupilumab Reduces COPD Exacerbations, Shows Promise for Personalized Treatment: Study Finds Medha Baranwal29 April 2025 8:00 PM ISTUSA: A pooled analysis of two phase 3, randomized, double-blind, placebo-controlled trials has demonstrated the effectiveness of dupilumab as an...
FDA Approves Dupilumab as First New Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade Dr. Kamal Kant Kohli21 April 2025 9:15 PM ISTThe US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous urticaria (CSU) in patients aged...
Sanofi, Regeneron Pharma secures USFDA approval for Dupixent for chronic spontaneous urticaria Ruchika Sharma19 April 2025 1:15 PM ISTParis: Sanofi and Regeneron Pharma have received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the...
Sanofi Dupixent approved in Japan for COPD Ruchika Sharma30 March 2025 10:00 AM ISTDupixent is intended for injection under the skin (subcutaneous injection) and is given every other week.
USFDA grants priority review to Sanofi-Regeneron Dupixent for bullous pemphigoid Ruchika Sharma20 Feb 2025 12:30 PM ISTParis: Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license...
Dupilumab significantly Reduces COPD Exacerbations in Phase 3 Trials Dr. Shravani Dali17 Feb 2025 9:15 PM ISTResearchers have found in a phase 3 trials that Dupilumab significantly reduced moderate or severe COPD exacerbations compared to placebo in...
Dupilumab may reduce COPD exacerbations in patients regardless of emphysema status: Study Jacinthlyn Sylvia17 Nov 2024 8:00 PM ISTA new study published in the journal of Respiratory Medicine showed that patients with type 2 inflammation and chronic obstructive pulmonary disease...
Sanofi, Regeneron Dupixent sBLA accepted for USFDA review for chronic spontaneous urticaria Ruchika Sharma17 Nov 2024 4:15 PM ISTParis: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the resubmission of the...
Sanofi, Regeneron Dupixent approved in EU for young children with eosinophilic esophagitis Ruchika Sharma7 Nov 2024 3:55 PM ISTParis: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in...
Dupilumab improves Health-related quality of life among COPD patients: Study Jacinthlyn Sylvia23 Oct 2024 8:30 PM ISTA new study published in the Chest Journal showed that Dupilumab helps individuals with type 2 inflammation and chronic obstructive pulmonary disease...
Dupilumab therapy reduced atopic dermatitis symptoms in pediatric population, finds study Jacinthlyn Sylvia14 Oct 2024 8:30 PM ISTA new study published in the Journal of American Academy of Dermatology found that Dupilumab improved atopic dermatitis (AD) symptoms as well as...
FDA approves first biologic treatment for COPD Dr. Kamal Kant Kohli3 Oct 2024 7:30 AM ISTThe US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary...
